Cullgen

Cullgen Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, founded in 2018 and focused on first-in-class targeted protein degradation medicines. Its proprietary uSMITE (ubiquitin-mediated, small molecule-induced target elimination) platform harnesses the body's own ubiquitin-proteasome system to selectively degrade disease-causing intracellular proteins, including targets considered undruggable by conventional small molecules, and the company extends that chemistry into degrader-antibody conjugates (DACs). Its lead TRK degrader program has entered Phase 1 clinical dosing, and the company has partnered with Astellas and taken investment from AstraZeneca. Gyre Therapeutics completed an all-stock acquisition of Cullgen valued at approximately $300 million on 4 May 2026. Cullgen publishes a corporate marketing website only: profiling on 2026-08-04 found no developer portal, documentation, machine-readable API contract, package registry presence, or public code repositories.

Cullgen is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Drug Discovery.

Cullgen’s developer surface includes engineering blog and 9 more developer resources.

🌐 Visit website 📡 Source on GitHub

6.4/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyBiotechnologyPharmaceuticalsLife SciencesDrug DiscoveryTargeted Protein DegradationOncologyClinical Stage

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 6.4/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.4 / 17

Commercial Clarity 0.0 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 1.1 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/cullgen: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Company 6

The organization behind the API

Website

About

Blog

Careers

LinkedIn

Twitter

Twitter

Other 1

Properties that don't map to a standard resource type

SecondaryMarket

SecondaryMarket

Source (apis.yml)

aid: cullgen
name: Cullgen
image: https://images.squarespace-cdn.com/content/64fa49d6dc6a8807524aa6c6/6a0a0ac8-3bf2-40b4-9f81-547d92175843/cullgen+logo+with+drop+shadow+more+blurry.png?format=1500w&content-type=image%2Fpng
description: 'Cullgen Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, founded in
  2018 and focused on first-in-class targeted protein degradation medicines. Its proprietary uSMITE (ubiquitin-mediated, small
  molecule-induced target elimination) platform harnesses the body''s own ubiquitin-proteasome system to selectively degrade
  disease-causing intracellular proteins, including targets considered undruggable by conventional small molecules, and the
  company extends that chemistry into degrader-antibody conjugates (DACs). Its lead TRK degrader program has entered Phase
  1 clinical dosing, and the company has partnered with Astellas and taken investment from AstraZeneca. Gyre Therapeutics
  completed an all-stock acquisition of Cullgen valued at approximately $300 million on 4 May 2026. Cullgen publishes a corporate
  marketing website only: profiling on 2026-08-04 found no developer portal, documentation, machine-readable API contract,
  package registry presence, or public code repositories.'
url: https://raw.githubusercontent.com/api-evangelist/cullgen/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
x-api-surface: none
specificationVersion: '0.20'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Discovery
- Targeted Protein Degradation
- Oncology
- Clinical Stage
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/cullgen-domain-security.yml
- type: LLMsTxt
  url: llms/cullgen-llms.txt
- type: Website
  url: https://www.cullgen.com/
- type: About
  url: https://www.cullgen.com/about-us
- type: Blog
  url: https://www.cullgen.com/news-press-releases
- type: Contact
  url: https://www.cullgen.com/contact-us
- type: Careers
  url: https://www.cullgen.com/careers-1
- type: LinkedIn
  url: https://www.linkedin.com/company/cullgen
- type: Twitter
  url: https://twitter.com/CullgenInc
- type: SecondaryMarket
  url: https://forgeglobal.com/cullgen_stock/
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 2
  pass: local-v1